Overview

A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia

Status:
Completed
Trial end date:
2013-12-10
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of PA21 in hemodialysis patients with hyperphosphatemia
Phase:
Phase 3
Details
Lead Sponsor:
Kissei Pharmaceutical Co., Ltd.
Treatments:
Sevelamer